Jonas Salk created a vaccine against polio that has been used since 1955; Albert Sabin created another version that has been on the market since 1961. Together, these two vaccines have nearly eliminated polio from the...
In a huge new discovery, scientists may have just found a possible new vaccine for a very common sexually transmitted disease. Chlamydia is a relatively common sexually transmitted infection that is mainly treatable and...
Nanoparticle-encapsulated mRNAs successfully vaccinate mice against pathogens. Vaccination has improved health and lengthened life spans over the last two centuries, but it takes time to develop vaccines in response to...
The protection provided by the world’s first malaria vaccine all but disappears after seven years, according to a new study. A phase-two clinical trial of Mosquirix (RTS,S) in Kenya showed just 4 percent effectiveness...
Researchers experimenting with harmless strains of E. coli — yes, the majority of E. coli are safe and important to healthy human digestion — are working toward that goal. They have developed an E. coli...
Tests in mice show the vaccines work against Ebola, influenza, and a common parasite. MIT engineers have developed a new type of easily customizable vaccine that can be manufactured in one week, allowing it to be...
A group of scientists are seeking to develop a drug against the virus using lymph nodes since they store immune system of humans. The immune system cells found in lymph nodes could help develop a vaccine against HIV...
A super-vaccine to prevent both Zika and dengue fever is on the horizon after scientists found that the viruses can be neutralised by the same antibodies. Antibodies work by combining with bacteria and viruses so that...
An experimental vaccine against malaria known as Mosquirix—or RTS,S—weakens over time and is only about four percent effective over a seven-year span, researchers said Wednesday. The findings, published in the New...
Takeda announced that it has dosed the first subject in a Phase 2b field efficacy trial of Takeda’s norovirus vaccine candidate (TAK-214), the only norovirus vaccine candidate in human clinical trials. The Phase 2b...